John LaMattina is the former head of Pfizer R&D. He writes about the pharmaceutical industry at Forbes, and is the author of Drug Truths: Dispelling The Myths Of R&D (Wiley, 2008) and Devalued And Distrusted: Can The Pharmaceutical Industry Restore Its Broken Image? (Wiley, 2013). He’s based in Stonington, Connecticut.
Segment
Read More
12:22
21st Century Cures Act Will Hasten Drug Approval
Patient advocates say the Act will get life-saving new drugs to patients faster. But critics contend that looser FDA regulations will raise the number of unsafe and ineffective drugs that make it to consumers.